Background:
Retinal vein occlusion (RVO) occurs when there is partial or complete obstruction of a retinal vein, and it is classified by the location of the occlusion. An obstruction of the retinal vein at or posterior to the optic nerve head is a central retinal vein occlusion (CRVO), and complete or partial obstruction at a branch or tributary of the central retinal vein is a branch retinal vein occlusion (BRVO).
Vision loss associated with a vein occlusion usually occurs from macular ischemia or edema, retinal hemorrhages, vitreous hemorrhage, and epiretinal membrane formation. Major risk factors for RVO includes older age (over 40 years of age), arteriosclerosis, systemic arterial hypertension, and diabetes. Specific risk factors associated with BRVO and CRVO are detailed in this Preferred Practice Pattern (PPP). The recommendations of this PPP are based on Cochrane-identified reliable systematic reviews.
Rationale for treatment:
Macular edema may complicate both CRVOs and BRVOs. The first line of treatment for associated macular edema is anti-vascular endothelial growth factors (anti-VEGFs). Intravitreal corticosteroids, with the associated risk of glaucoma and cataract formation, have demonstrated efficacy. Also, laser photocoagulation surgery in BRVO has a potential role in treatment.
Patients who develop iris neovascularization or retinal neovascularization following a CRVO, peripheral panretinal photocoagulation (PRP) treatment is advised. Note, PRP may decrease progression of iris neovascularization and may prevent neovascular glaucoma. Anti-VEGF can be used in an adjunctive manner if angiogenesis continues after PRP.
Care Process: Patient outcome criteria are to improve or stabilize visual function and vision-related quality of life, detection and treatment of neovascular complications and macular edema, and control of blood pressure, diabetes and blood glucose, and other risk factors through direct communication and coordination of care with the patient's primary care physician. Patients under evaluation for RVO should undergo thorough medical history, ocular exam, and appropriate retinal imaging as needed.
Management recommendations are detailed in this PPP, which includes surgical management and follow-up evaluation. Due to the complexities of the diagnosis and treatment for RVO, the ophthalmologist should be familiar with the specific recommendations of relevant clinical trials. Ophthalmologists should involve primary care physicians of RVO patients as part of their management for systemic conditions.
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As a service to its members and the public, the American Academy of Ophthalmology has developed a series of Preferred Practice Pattern® guidelines that identify characteristics and components of quality eye care. Appendix 1 describes the core criteria of quality eye care.
The Preferred Practice Pattern® guidelines are based on the best available scientific data as interpreted by panels of knowledgeable health professionals. In some instances, such as when results of carefully conducted clinical trials are available, the data are particularly persuasive and provide clear guidance. In other instances, the panels have to rely on their collective judgment and evaluation of available evidence.
These documents provide guidance for the pattern of practice, not for the care of a particular individual. While they should generally meet the needs of most patients, they cannot possibly best meet the needs of all patients. Adherence to these PPPs will not ensure a successful outcome in every situation. These practice patterns should not be deemed inclusive of all proper methods of care or exclusive of other methods of care reasonably directed at obtaining the best results. It may be necessary to approach different patients' needs in different ways. The physician must make the ultimate judgment about the propriety of the care of a particular patient in light of all of the circumstances presented by that patient. The American Academy of Ophthalmology is available to assist members in resolving ethical dilemmas that arise in the course of ophthalmic practice.
Preferred Practice Pattern® guidelines are not medical standards to be adhered to in all individual situations. The Academy specifically disclaims any and all liability for injury or other damages of any kind, from negligence or otherwise, for any and all claims that may arise out of the use of any recommendations or other information contained herein.
References to certain drugs, instruments, and other products are made for illustrative purposes only and are not intended to constitute an endorsement of such. Such material may include information on applications that are not considered community standard, that reflect indications not included in approved US Food and Drug Administration (FDA) labeling, or that are approved for use only in restricted research settings. The FDA has stated that it is the responsibility of the physician to determine the FDA status of each drug or device he or she wishes to use, and to use them with appropriate patient consent in compliance with applicable law.
Innovation in medicine is essential to ensure the future health of the American public, and the Academy encourages the development of new diagnostic and therapeutic methods that will improve eye care. It is essential to recognize that true medical excellence is achieved only when the patients' needs are the foremost consideration.
All Preferred Practice Pattern® guidelines are reviewed by their parent panel annually or earlier if developments warrant and updated accordingly. To ensure that all PPPs are current, each is valid for 5 years from the approved by date unless superseded by a revision. Preferred Practice Pattern guidelines are funded by the Academy without commercial support. Authors and reviewers of PPPs are volunteers and do not receive any financial compensation for their contributions to the documents. The PPPs are externally reviewed by experts and stakeholders, including consumer representatives, before publication. Preferred Practice Pattern® guidelines should be clinically relevant and specific enough to provide useful information to practitioners. Where evidence exists to support a recommendation for care, the recommendation should be given an explicit rating that shows the strength of evidence. To accomplish these aims, methods from the Scottish Intercollegiate Guideline Network 1 (SIGN) and the Grading of Recommendations Assessment, Development and Evaluation 2 (GRADE) group are used. GRADE is a systematic approach to grading the strength of the total body of evidence that is available to support recommendations on a specific clinical management issue. Organizations that have adopted GRADE include SIGN, the World Health Organization, the Agency for Healthcare Research and Policy, and the American College of Physicians. 3 ◆ All studies used to form a recommendation for care are graded for strength of evidence individually, and that grade is listed with the study citation.
◆ To rate individual studies, a scale based on SIGN 1 is used. The definitions and levels of evidence to rate individual studies are as follows:
I++
High-quality meta-analyses, systematic reviews of randomized controlled trials (RCTs), or RCTs with a very low risk of bias I+ Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias I-Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias II++ High-quality systematic reviews of case-control or cohort studies High-quality case-control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal II+ Well-conducted case-control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal II-Case-control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal III Nonanalytic studies (e.g., case reports, case series) ◆ Recommendations for care are formed based on the body of the evidence. The body of evidence quality ratings are defined by GRADE 2 as follows: The loss of vision that is associated with a vein occlusion usually occurs from macular ischemia or edema, retinal hemorrhages, vitreous hemorrhage, epiretinal membrane formation, rubeosis iridis, and neovascular glaucoma. 4 Other findings associated with RVOs include retinal arterial macroaneurysm formation and cilioretinal artery occlusions.
It is now known that all vein occlusions are ischemic to varying degrees as the retina drained by the occluded vessels releases hypoxia related factors such as VEGF as described in the paper by Campochiaro et al, thus there is a spectrum of non-perfusion. 9 The patient population includes people over 40 years of age. The most common age range is from the 6 th to the 7 th decade. 10, 11 Retinal vein occlusions are relatively uncommon in individuals under age 40. and is estimated to affect more than 16 million people worldwide. 11, 12 The prevalence appears to be similar in East Asia and in the United States. Branch retinal vein occlusions occur six to seven times more commonly than CRVOs. 13 African Americans have an incidence of CRVO similar to white Americans, and a gender predilection does not seem to exist. 11 The prevalence of RVOs might be lower in East Indians (0.76/100), with a similar six-fold higher prevalence of BRVO compared with CRVO. 14 In a Japanese study, the 9-year incidence was 3% for any RVO, and there was a nine-fold higher rate of BRVO compared with CRVO. 15 The incidence rate is about 48/100,000 person-years in Korea. 16 In the United States, the 5-year incidence rate is 0.8 per 100, whereas the 15-year incidence is 2.3 per 100 for individuals 40 years of age or older at baseline. 14, 16 In China, the 10-year incidence rate for those 40 years of age or older at baseline is 1.9 per 100. 13 In a pooled group of 68,751 subjects for CRVO (CI = 0.6-1.0). 11 The main risk factor for both CRVO and BRVO is older age. A prior RVO is a risk factor for an RVO in the fellow eye. 12 The chance of a person with a pre-existing CRVO developing a CRVO in the fellow eye is 1% per year. 17 Patients with a BRVO in one eye have a 10% risk of developing an RVO of either type in the fellow eye over 3 years. 18, 19 The other major risk factors for BRVO differ from those for CRVO or hemi-CRVO. Risk of BRVO is more likely associated with local vascular factors (arterial-venous crossing changes) rather than local ocular factors. Risk factors for BRVO include systemic conditions such as arterial hypertension, hyperlipidemia, diabetes, and coronary artery disease. 20, 21 Controversy exists regarding the contribution of other hematologic factors, such as factor V Leiden and homocysteinemia, in the development of BRVO. These hematologic factors may be more likely to contribute to the development of CRVO, although there is not uniform agreement.
Retinal phlebitis may be associated with BRVO. Risk factors for CRVO include carotid occlusive disease and sleep apnea as well as glaucoma. 22 In selected cases, elevated homocysteine levels have been associated with CRVO. Fifty-eight percent of patients with CRVO onset at an age younger than 50 were found to have a nontraditional risk factor on systemic/laboratory evaluation. [23] [24] [25] In a cohort with systemic lupus erythematosus, the incidence of CRVO was 3.5 times higher than in a control population. 26 A recent meta-analysis and systematic review published in Retina suggests patients with any RVO have an increased risk of cardiovascular events and all-cause mortality. 27 A patient with a CRVO is likely to develop macular edema. Additionally, approximately 25% of patients with CRVO will develop iris neovascularization, and occasional patients may develop retinal neovascularization. Patients with a CRVO have a higher mortality rate than controls in an ageadjusted general population. This additional risk is due to a higher prevalence of cardiovascular disease and diabetes. 28 An extensive study of the natural history of RVO categorized BRVOs as mild, moderate, or marked, based on the level of capillary nonperfusion seen angiographically. 18 occasionally hard exudates or even retinal detachment in the affected region. 29 Over time, the acute process resolves and the hemorrhages may clear, along with the cotton wool spots. In general, the macular edema persists and is a common cause of visual dysfunction unless appropriately treated.
Collaterals may also develop between the retinal venules and the choroidal circulation at the disc following a CRVO and between the superior and inferior retinal veins in a BRVO.
The prognosis for vision loss due to BRVO depends on the degree of nonperfusion and the location of the occlusion. 30 The ischemia. 30 The severity of the occlusion and extent of ischemia are important prognostic factors for the final visual acuity deficit resulting from BRVO. 31 Long-standing BRVO is usually characterized by minimal intraretinal blood and resolution of cotton wool spots with mild residual venous tortuosity and collateral vessels adjacent to the affected area.
Macular edema may persist yet may also resolve over time, leaving secondary retinal pigment epithelial atrophy and suboptimal visual acuity. Macular edema causes a substantial decrease in vision-related quality of life. 30 Epiretinal membrane often develops in eyes affected by BRVO.
For individuals who develop iris neovascularization or retinal neovascularization following a CRVO, the best treatment is dense peripheral panretinal photocoagulation (PRP). 32 Although PRP does not usually improve the visual acuity, it decreases the risk of progression to iris neovascularization and may prevent neovascular glaucoma. Additionally, anti-vascular endothelial growth factor (anti-VEGF) agents can be used in an adjunctive manner when the complete PRP is insufficient to control angiogenesis. 32, 33 Anti-vascular endothelial growth factor agents are commonly used to treat the macular edema, reduce the severity of anterior segment neovascularization, and lower the risk of ocular angiogenesis. 33 Published data estimates the incidence of macular edema in all BRVOs to be 30%. 34 Patients In eyes with BRVO and macular edema, anti-VEGF injections, [36] [37] [38] [39] [40] focal laser treatment, 30 and intravitreal steroids 41 all have demonstrated therapeutic benefit. [42] [43] [44] In eyes with CRVO and macular edema, anti-VEGF [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] and intravitreal steroids 56 have demonstrated benefit. Currently, three anti-VEGF agents are used routinely for the treatment of macular edema associated with RVO; two (ranibizumab and aflibercept) are approved by the U.S. Food and Drug Administration (FDA). Although, bevacizumab remains off-label for ophthalmologic conditions, there is evidence demonstrating its efficacy and safety. [53] [54] [55] Intravitreal corticosteroids (triamcinolone and dexamethasone implant) are considered second line because of significant ocular side effects, such as secondary glaucoma and cataract formation. 56 In patients with a BRVO and neovascularization of the retina, retinal laser photocoagulation surgery in the area of nonperfusion helps to decrease the risk of a vitreous hemorrhage. 57 In patients with CRVO with retinal and/or iris neovascularization, dense peripheral PRP is indicated. 17 Occasionally, initial treatment with an anti-VEGF agent might be helpful for an immediate but nonsustained benefit and may also improve the ability to deliver a complete laser treatment. 33 Patient outcome criteria include the following: An initial history should consider the following elements: The initial examination should include the following elements:
◆ Visual acuity 12 ◆ Pupillary assessment for a relative afferent pupillary defect that corresponds to the level of ischemia and is also predictive for eyes at risk for neovascularization ◆ Slit-lamp biomicroscopy, looking carefully for fine, abnormal, new iris vessels ◆ IOP ◆ Gonioscopy prior to dilation. This is important to perform, especially in cases of an ischemic CRVO, when there is an elevated IOP or when iris neovascularization risk is high. Several studies have demonstrated that in eyes with RVO, noninvasive optical coherence tomography angiography (OCTA) is similar to fluorescein angiography (FA) in detecting capillary nonperfusion, enlarged foveal avascular zone, and vascular abnormalities. 60, 61 This promising technology is currently limited by image artifacts and limited field of view.
Future studies are needed to determine its clinical utility and if it can replace FA in the future.
Fluorescein angiography is used to evaluate the extent of the vascular occlusion, the degree of ischemia (ischemic as defined by the CVOS eyes with 10 disc areas of capillary nonperfusion on standard FA vs. nonischemic), and the extent of macular edema. Angiography can identify macular capillary nonperfusion that may explain the associated vision loss as well as the response to therapy. It is a useful technique to distinguish collateral vessels, which do not leak fluorescein in later frames, from retinal neovascularization that is associated with late leakage. It can identify regions of peripheral nonperfusion, helping to guide effective laser treatment or possibly detecting areas of untreated retinal capillary nonperfusion that may explain persistent retinal or disc neovascularization that remains present after prior laser treatment. Recent advances in wide-field FA have enabled its use to evaluate peripheral nonperfusion, yet current data on the benefits of this technique are inconclusive. Some have proposed that the degree of ischemia on wide-field FA can help classify a CRVO as ischemic or nonischemic as well as determine the risk of conversion of a CRVO from nonischemic to ischemic. 62 As the use of anti-VEGF agents and intraocular corticosteroids has increased for the treatment of macular edema, the use of grid laser treatment has decreased. Therefore, the need for FA has also declined. However, FA remains a valuable tool and should be considered by ophthalmologists who diagnose and treat patients who have retinal vascular
disease.
An ophthalmologist who orders an FA must obtain informed consent and be aware of both common and rare potential risks associated with the procedure, including death in about 1/200,000 patients. 63 Each angiography facility should have in place an emergency care plan and a clear protocol to manage known risks and complications. Fluorescein dye crosses the placenta into the fetal circulation, 64 The extent of the systemic evaluation is dependent on the patient's age and medical history.
Discussion with the primary care doctor is important, since a patient who has had an RVO is at risk for developing an RVO in the fellow eye and has a higher risk of cardiovascular disease and cerebrovascular accidents. 12, 21 Clear guidelines on systemic testing are lacking.
There is a strong relationship between BRVO and systemic vascular disorders such as arterial hypertension and peripheral vascular disease. Older age and systemic vascular disorders are the strongest risk factors for RVO. 65 A recent meta-analysis of published studies suggests that 48% of RVO is attributable to hypertension, 20% to hyperlipidemia, and 5% to diabetes. 35 It is known that arteriovenous nicking, ocular perfusion pressure, and focal arteriolar narrowing are related to an increased risk of developing a BRVO. 21, 29 Data are inconclusive in determining whether lowering blood pressure and/or serum lipid levels improves visual acuity or the complications from RVO. 35 Consequences of untreated RVOs and vision loss are an economic burden on patients, their family, and society. Anti-VEGF agents, laser and intravitreal steroids are cost-effective for the management of RVOs. The choice of treatment should be individually tailored based on discussion between the patient, family, and physician. 66, 67 The current treatment strategies for BRVO target the sequelae of the venous occlusion (i.e., CME and NVD/NVE) rather than to attempt to treat the occlusion itself.
Clinical trials have evaluated the efficacy of anti-VEGF agents and/or intravitreal corticosteroid injections.
Multiple level I studies have demonstrated the efficacy of these agents in the treatment of macular edema associated with BRVO. 37 months demonstrated vision improvement but did not achieve the level of vision gain compared with those eyes that were randomized to ranibizumab initially-demonstrating that delay in treatment can be deleterious. 42 The benefits of ranibizumab seen at 6 months were generally maintained by month 12. 37 The HORIZON trial included all patients who completed the BRAVO trial and entered an open-label multicenter extension trial. Patients were followed quarterly for 12 months with repeat injections of 0.5 mg ranibizumab, used at the investigator's discretion. 51 Approximately half of the eyes in HORIZON achieved resolution of edema and 80% had visual acuity of better than or equal to 20/40. However, approximately half of the eyes enrolled in the HORIZON extension study received grid laser photocoagulation surgery at some point during the study period. These studies used ranibizumab, whereas other smaller, level II studies have demonstrated the efficacy of bevacizumab for BRVO-associated macular edema. 39, 40, 65 The VIBRANT trial was a randomized double-masked phase 3 trial that demonstrated the efficacy of aflibercept over grid laser treatment for macular edema in BRVO. 36 Two systematic reviews between 2013 and 2016 have confirmed the efficacy of anti-VEGF injections for treatment of macular edema associated with RVO with minimal side effects. 68, 69 ( I++, Good quality, Strong recommendation)
In general, the use of topical povidone iodine is recommended before all intravitreal injections, whereas the use of routine antibiotic eye drops is not recommended. 70 anti-VEGF treatment. 71 Intraocular pressure elevations are particularly common with the use of intravitreal corticosteroids and the corticosteroid implants. In conclusion, because of the favorable risk-to-benefit profile, anti-VEGF agents are the preferred initial therapy for treatment of macular edema related to BRVO. Either corticosteroids and/or grid laser treatment should be considered when there is a failure to respond or an inadequate response.
Several randomized controlled trials have also shown the efficacy of anti-VEGF agents in treating macular edema with CRVO. 45, 48, 52, 72 comparison of aflibercept to bevacizumab for macular edema from CRVO showed that aflibercept was similar to bevacizumab in mean visual acuity at 6 months (primary outcome). 76 From months 6 to 12, patients in SCORE2 were then stratified based on their response to the original monthly treatment as good, poor, or marginal response. Those with a good response were then given the original treatment drug monthly or on a treat-andextend protocol basis. Patients in the treat-and-extend protocol received about one to two fewer injections compared with the monthly regimen. However, because of the widths of the confidence intervals on visual acuity at 12 months, caution is advised before concluding that the two regimens yield similar visual outcomes. 77 For eyes classified as poor responders to aflibercept at 6 months, dexamethasone rescue was used. 77 Aflibercept was used for eyes with a marginal response to bevacizumab. 77 There is a role for intravitreal steroids such as triamcinolone, dexamethasone and other corticosteroids that have been shown to be efficacious for macular edema associated with
CRVO, yet there are known associated risks of cataracts and glaucoma. 56, 72, 78 The SCORE study for BRVO evaluated the use of two doses of intravitreal corticosteroids (triamcinolone 1 mg and 4 mg) versus macular grid laser therapy in 411 eyes randomized to one of the three treatment arms in a 1:1:1 fashion and followed for 12 months. 41 After 1
year, approximately one-third of eyes in the laser treatment group, one-third of eyes in the triamcinolone1-mg group, and one-third of eyes in the triamcinolone 4-mg group gained 15 or more letters. The mean gain in best-corrected visual acuity was 4 to 5 letters in all groups; however, patients in either of the corticosteroid groups were more likely to develop cataract or elevated IOP than those who received laser treatment. The SCORE recommendations for BRVO were to consider macular grid laser treatment in eyes with BRVO and perfused macular edema leading to vision loss because the efficacy was similar in all treatment arms.
The SCORE CRVO trial included 271 people aged 68 years on average. 56 Seventy-three percent of patients with CRVO had high blood pressure and 23% percent had diabetes.
Patients in the corticosteroid medication groups received an average of two injections in the first 12 months of the study.
After 1 year, 27% of patients in the 1-mg group and 26% of patients in the 4-mg group experienced a substantial visual gain of 3 or more lines of visual acuity. Only 7% of patients in the observation group experienced a similar visual gain. Therefore, patients in the corticosteroid treatment groups were much more likely to have a substantial visual gain at 1 year. These results persisted up to 2 years.
However, participants who received the 4-mg dose had the highest rates of cataract formation, cataract surgery, and elevated IOP within the eye, indicating a preference for the 1-mg dose. 56 The GENEVA study evaluated the use of the intravitreal dexamethasone implant (Ozurdex®, Allergan, Inc., Irvine, CA) in two doses compared with sham injection in eyes with either a CRVO or a BRVO. 79 The study included pooled data from 1131 patients, 34%
with CRVO and 66% with BRVO, and showed that in the BRVO eyes treatment with either the 0.35-mg or the 0.7-mg dose implant had no efficacy at 6 months. However, there was significant visual acuity gain at 90 days that was lost at 6 months. Results from an open-label extension beyond 6 months were similar to the initial study, showing visual acuity gains up to 90 days, then loss of a treatment effect at 1 year. 72 Cataract formation and elevated IOP were seen more frequently at 1 year than at 6 months (16% had an elevated IOP of 25 mmHg or greater). The dexamethasone implant was FDA approved in 2009 for the treatment of macular edema due to CRVO and BRVO.
The COBALT study has shown that with retreatment using the dexamethasone implant as often as every 4 months, significant visual acuity gains can be achieved for eyes with macular edema secondary to a BRVO. 80 In fact, mean visual acuity improvement was 18.6 ± 12.9 and 15.3 ± 15.0 letters at 6 and 12 months, respectively. There was a rapid response, with approximately 70% of maximum treatment response seen at 1 week. Incidence of IOP elevation was 18% and cataract incidence was 16% at one year.
A third corticosteroid implant, fluocinolone, has also been shown to be beneficial in the treatment of BRVO-associated macular edema up to 3 years following injection. There were improvements in both edema and visual acuity, 81 but fluocinolone is not yet approved by the FDA for this indication. Glaucoma and cataract formation were reported side effects in this study.
A Cochrane systemic review questioned the results of SCORE because of incomplete outcome data and the GENEVA study because of selective reporting and found that there was insufficient evidence to determine if steroids are beneficial or not. 82 (I+, Good quality, Strong recommendation) A meta-analysis found no difference in visual improvement for treatment of macular edema from CRVO with bevacizumab, ranibizumab, aflibercept and triamcinolone. However, steroid and IOP risks associated with steroids make anti-VEGF more favorable as initial therapy. 78 demonstrated that adding laser to ranibizumab did not result in a better visual outcome or reduce the need for treatment. In the RELATE study, scatter laser to peripheral ischemic areas did not decrease the macular edema. 85 The Central Vein Occlusion Study (CVOS) did not show any value of focal photocoagulation for macular edema in patients with CRVO. 17 For patients with iris or angle neovascularization, the CVOS recommended complete peripheral PRP. 17 Currently, anti-VEGFs are being used as an adjunct to treat iris or angle neovascularization. There is no phase 3 clinical trial evidence for this usage.
The follow-up evaluation includes a history and examination.
A follow-up history should include changes in the following: [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] The American Academy of Ophthalmology has a stated position and a policy statement on the role of the ophthalmologist in the delivery of intravitreal agents. 105 Outside of the United States, there are varying practice patterns. [106] [107] [108] The ophthalmologist should refer patients with an RVO to a primary care physician for appropriate management of their systemic condition and should communicate examination results to the physician managing the patient's ongoing medical care. 35 The risk to the fellow eye should also be communicated to both the primary care provider and the patient. 12, 21 An Eye MD Examination Report Form is available from the American Academy of Ophthalmology. 109 Some patients with RVO will lose substantial vision despite being treated according to the recommendations in this document.
Patients whose conditions fail to respond to therapy and those for whom further treatment is unavailable should be provided with proper professional support and offered referral for counseling, vision rehabilitation, or social services as appropriate. 110 Vision rehabilitation helps to restore some functional ability, 111 and patients with functionally limiting postoperative visual impairment should be referred for vision rehabilitation and social services. 110 More information on vision rehabilitation, including materials for patients, is available at www.aao.org/low-vision-and-vision-rehab.
Very few studies have evaluated the cost/benefit ratio of the various treatment types for RVO. One study evaluated the cost/benefit ratio of treatment methods for macular edema due to various etiologies. The dollars per quality-adjusted life years (QALY) for treatment of BRVO with macular edema ranges between approximately $800 and $26,000 and for CRVO with macular edema it ranges between approximately $1,400 and $16,000. These are cost-effective treatments. 66 The same study also concluded that the benefit conveyed by pharmacologic therapy for visual acuity, although statistically significant, may be modestly beneficial (i.e., 1 line or less of visual acuity gained). This study demonstrates the wide range of cost parameters for macular edema treatment, ranging from a low of $1,326 for laser to $23,119 for a 1-year course of ranibizumab treatment, a 17-fold difference.
Costs per visual acuity line-year ranged from $25 to $754. 66 A recent study reported on the direct medical costs for treating CRVO and BRVO in working-age and Medicare populations. 67 The authors found that health care utilization and expenditures for patients with BRVO or CRVO were significantly greater than those for control subjects without these diseases Providing quality care is the physician's foremost ethical obligation, and is the basis of public trust in physicians.
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Quality ophthalmic care is provided in a manner and with the skill that is consistent with the best interests of the patient. The discussion that follows characterizes the core elements of such care.
The ophthalmologist is first and foremost a physician. As such, the ophthalmologist demonstrates compassion and concern for the individual, and utilizes the science and art of medicine to help alleviate patient fear and suffering. The ophthalmologist strives to develop and maintain clinical skills at the highest feasible level, consistent with the needs of patients, through training and continuing education. The ophthalmologist evaluates those skills and medical knowledge in relation to the needs of the patient and responds accordingly. The ophthalmologist also ensures that needy patients receive necessary care directly or through referral to appropriate persons and facilities that will provide such care, and he or she supports activities that promote health and prevent disease and disability.
The ophthalmologist recognizes that disease places patients in a disadvantaged, dependent state. The ophthalmologist respects the dignity and integrity of his or her patients and does not exploit their vulnerability.
Quality ophthalmic care has the following optimal attributes, among others.
◆ The essence of quality care is a meaningful partnership relationship between patient and physician. The ophthalmologist strives to communicate effectively with his or her patients, listening carefully to their needs and concerns. In turn, the ophthalmologist educates his or her patients about the nature and prognosis of their condition and about proper and appropriate therapeutic modalities. This is to ensure their meaningful participation (appropriate to their unique physical, intellectual and emotional state) in decisions affecting their management and care, to improve their motivation and compliance with the agreed plan of treatment, and to help alleviate their fears and concerns. ◆ The ophthalmologist uses his or her best judgment in choosing and timing appropriate diagnostic and therapeutic modalities as well as the frequency of evaluation and follow-up, with due regard to the urgency and nature of the patient's condition and unique needs and desires.
◆ The ophthalmologist carries out only those procedures for which he or she is adequately trained, experienced and competent, or, when necessary, is assisted by someone who is, depending on the urgency of the problem and availability and accessibility of alternative providers. ◆ Patients are assured access to, and continuity of, needed and appropriate ophthalmic care, which can be described as follows.
◆
The ophthalmologist treats patients with due regard to timeliness, appropriateness, and his or her own ability to provide such care.
The operating ophthalmologist makes adequate provision for appropriate pre-and postoperative patient care.
◆ When the ophthalmologist is unavailable for his or her patient, he or she provides appropriate alternate ophthalmic care, with adequate mechanisms for informing patients of the existence of such care and procedures for obtaining it.
The ophthalmologist refers patients to other ophthalmologists and eye care providers based on the timeliness and appropriateness of such referral, the patient's needs, the competence and qualifications of the person to whom the referral is made, and access and availability.
The ophthalmologist seeks appropriate consultation with due regard to the nature of the ocular or other medical or surgical problem. Consultants are suggested for their skill, competence, and accessibility. They receive as complete and accurate an accounting of the problem as necessary to provide efficient and effective advice or intervention, and in turn respond in an adequate and timely manner.
The ophthalmologist maintains complete and accurate medical records.
On appropriate request, the ophthalmologist provides a full and accurate rendering of the patient's records in his or her possession.
The ophthalmologist reviews the results of consultations and laboratory tests in a timely and effective manner and takes appropriate actions.
The ophthalmologist and those who assist in providing care identify themselves and their profession.
For patients whose conditions fail to respond to treatment and for whom further treatment is unavailable, the ophthalmologist provides proper professional support, counseling, rehabilitative and social services, and referral as appropriate and accessible. ◆ Prior to therapeutic or invasive diagnostic procedures, the ophthalmologist becomes appropriately conversant with the patient's condition by collecting pertinent historical information and performing relevant preoperative examinations. Additionally, he or she enables the patient to reach a fully informed decision by providing an accurate and truthful explanation of the diagnosis; the nature, purpose, risks, benefits, and probability of success of the proposed treatment and of alternative treatment; and the risks and benefits of no treatment. ◆ The ophthalmologist adopts new technology (e.g., drugs, devices, surgical techniques) in judicious fashion, appropriate to the cost and potential benefit relative to existing alternatives and to its demonstrated safety and efficacy.
◆ The ophthalmologist enhances the quality of care he or she provides by periodically reviewing and assessing his or her personal performance in relation to established standards, and by revising or altering his or her practices and techniques appropriately. ◆ The ophthalmologist improves ophthalmic care by communicating to colleagues, through appropriate professional channels, knowledge gained through clinical research and practice. This includes alerting colleagues of instances of unusual or unexpected rates of complications and problems related to new drugs, devices or procedures. ◆ The ophthalmologist provides care in suitably staffed and equipped facilities adequate to deal with potential ocular and systemic complications requiring immediate attention.
◆ The ophthalmologist also provides ophthalmic care in a manner that is cost effective without unacceptably compromising accepted standards of quality. 
